ZNRF1 Inhibitors
Chemical inhibitors of ZNRF1 function by modulating the activity of enzymes that phosphorylate proteins interacting with this ubiquitin ligase. For instance, GSK-3 inhibitors such as SB-216763, LiCl, BIO, CHIR99021, Indirubin-3'-monoxime, TWS119, AR-A014418, Tideglusib, and AZD1080 can inhibit the phosphorylation of substrates that may have a role in the function of ZNRF1. By preventing the addition of phosphate groups to these substrates, the inhibitors can alter the interaction between ZNRF1 and its substrates. GSK-3 is known for targeting various proteins for phosphorylation, which can then interact with ZNRF1, affecting its ability to tag these proteins with ubiquitin. Without the appropriate phosphorylation signals, the usual targets of ZNRF1 may not be properly recognized, leading to a decrease in ZNRF1-mediated ubiquitination.
On the other hand, HDAC inhibitors like Valproic Acid, Trichostatin A, and Vorinostat engage in a different mechanism of action. They do not directly inhibit the kinase activity but instead alter the acetylation status of proteins. The change in acetylation can influence the protein-protein interactions that are crucial for ZNRF1 function. Proteins that are normally ubiquitinated by ZNRF1 may have altered acetylation patterns, which can affect how ZNRF1 recognizes and processes these substrates. By changing the acetylation landscape of these proteins, HDAC inhibitors can disrupt the normal function of ZNRF1, leading to reduced ubiquitination of its targets. This modulation of protein acetylation serves as an indirect way to regulate the activity of ZNRF1 without directly competing with its substrate binding or ubiquitin ligase activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB-216763 is a glycogen synthase kinase 3 (GSK-3) inhibitor. ZNRF1 is regulated by phosphorylation, and GSK-3 is known to phosphorylate substrates that can interact with ZNRF1, potentially affecting its ubiquitin ligase activity. Inhibition of GSK-3 by SB-216763 could lead to reduced phosphorylation of these substrates, thus inhibiting ZNRF1 activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride is another inhibitor of GSK-3. As GSK-3 is involved in the phosphorylation of proteins that may interact with ZNRF1, LiCl may inhibit this phosphorylation, thereby potentially inhibiting ZNRF1 function. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
6-Bromoindirubin-3'-oxime (BIO) is a specific GSK-3 inhibitor. It can inhibit the phosphorylation of GSK-3 substrates, thereby potentially decreasing the interaction with ZNRF1 and inhibiting its activity. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR99021 is a potent GSK-3 inhibitor and can prevent the phosphorylation of proteins that may interact with ZNRF1. By inhibiting GSK-3, CHIR99021 could indirectly inhibit ZNRF1 function. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This compound is a GSK-3 inhibitor, potentially reducing the phosphorylation of proteins that interact with ZNRF1, thereby indirectly inhibiting ZNRF1 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
AR-A014418 is a selective GSK-3 inhibitor. By inhibiting GSK-3, it could decrease the phosphorylation of molecules that interact with ZNRF1, indirectly inhibiting ZNRF1's activity. | ||||||
Tideglusib | 865854-05-3 | sc-507358 | 10 mg | $75.00 | ||
Tideglusib is an irreversible inhibitor of GSK-3. It may reduce the phosphorylation of downstream proteins that could interact with ZNRF1, potentially inhibiting ZNRF1 function. | ||||||
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone | sc-501166 | 5 mg | $540.00 | |||
AZD1080 is a GSK-3 inhibitor that can potentially reduce phosphorylation of proteins interacting with ZNRF1, indirectly inhibiting the ubiquitin ligase activity of ZNRF1. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic Acid is a histone deacetylase (HDAC) inhibitor, which can alter gene expression and protein interactions. It may change the acetylation status of proteins that interact with ZNRF1, indirectly inhibiting ZNRF1 function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is another HDAC inhibitor that can affect acetylation patterns of proteins. Altered acetylation might change the interaction landscape of ZNRF1, leading to an indirect inhibition of its activity. | ||||||